Literature DB >> 11604471

Rapamycin may prevent post-transplant lymphoma.

K Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11604471     DOI： 10.1093/jnci/93.20.1519

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.

Authors:  Vivek Subbiah; Robert E Brown; Mary F McGuire; Jamie Buryanek; Filip Janku; Anas Younes; David Hong
Journal:  Oncotarget       Date:  2014-01-15

2.  Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series.

Authors:  Farzaneh Ashrafi; Shahrzad Shahidi; Zeinab Ebrahimi; Mojgan Mortazavi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-01-01

3.  A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.

Authors:  Neel D Trivedi; Samantha Armstrong; Hongkun Wang; Marion Hartley; John Deeken; A Ruth He; Deepa Subramaniam; Heather Melville; Chris Albanese; John L Marshall; Jimmy Hwang; Michael J Pishvaian
Journal:  Cancer Med       Date:  2021-02-27       Impact factor: 4.452

4.  Inhibition of mTORC1 inhibits lytic replication of Epstein-Barr virus in a cell-type specific manner.

Authors:  Amy L Adamson; Brandi T Le; Brian D Siedenburg
Journal:  Virol J       Date:  2014-06-11       Impact factor: 4.099
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.